Skip to content
Sunlenca(lenacapavir sodium)
Sunlenca (lenacapavir sodium) is a small molecule pharmaceutical. Lenacapavir sodium was first approved as Sunlenca on 2022-08-17. It is used to treat hiv-1 in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Sunlenca
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lenacapavir sodium
Tradename
Company
Number
Date
Products
SUNLENCAGilead SciencesN-215973 RX2022-12-22
1 products, RLD, RS
SUNLENCAGilead SciencesN-215974 RX2022-12-22
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
sunlencaNew Drug Application2022-12-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv-1—D015497—
Agency Specific
FDA
EMA
Expiration
Code
LENACAPAVIR SODIUM, SUNLENCA, GILEAD SCIENCES INC
2027-12-22NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Lenacapavir Sodium, Sunlenca, Gilead Sciences Inc
112677992038-08-16DP
100719852037-08-17DS, DP
106548272037-08-17U-3507
99510432034-02-28DS, DPU-3507
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AX: Other antivirals in atc
— J05AX31: Lenacapavir
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20234——7
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLENACAPAVIR SODIUM
INNlenacapavir
Description
Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.
Classification
Small molecule
Drug classantivirals: viral capsid inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c([N-]S(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O.[Na+]
Identifiers
PDB—
CAS-ID2189684-45-3
RxCUI—
ChEMBL IDCHEMBL4802249
ChEBI ID—
PubChem CID138059678
DrugBankDB15673
UNII IDA9A0O6FB4H (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 135 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details